Skip to Content
Merck
All Photos(2)

Key Documents

MABN367

Sigma-Aldrich

Anti-SV2C Antibody, clone 4C8.1

clone 4C8.1, from mouse

Synonym(s):

Synaptic vesicle glycoprotein 2C, SV2C

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

4C8.1, monoclonal

species reactivity

mouse, human

technique(s)

immunohistochemistry: suitable
western blot: suitable

isotype

IgG2aκ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... SV2C(22987)

General description

The protein named Synaptic vesicle glycoprotein 2C (SV2C) and encoded by the human name named SV2C/KAA1054 is glycosylated membrane bound protein important in vesicle secretion. SV2C is part of the major facilitator superfamily of vesicle movement and fusion proteins and is particularly important is vesicle fusion by maintaining a readily releasable pool of secretory granules. Expressed in neural and endocrine cells primarily, SV2C is important for neurotransmission and hormone release. SV2C is enriched in small synaptic vesicles and adrenal microsomes but it is not present in chromaffin granules but is found in insulin granules and microvesicles in the pancreas. In the brain SV2C, in contrast to SV2A and SV2B, expression is restricted to certain regions. High levels of SV2C are found primarily in phylogenetically old brain regions such as the pallidum, the substantia nigra, the midbrain, the brainstem and the olfactory bulb, but SV2C is undetectable in the cerebral cortex and the hippocampus, and found at low levels in the cerebellar cortex. Recent research though also demonstrates that SV2C plays an important role in normal operation of the basal ganglia network and SV2C could also be involved in system adaptation during basal ganglia pathology.

Immunogen

Epitope: Cytoplasmic domain
GST-tagged recombinant protein corresponding to the cytoplasmic domain of human SV2C.

Application

Anti-SV2C Antibody, clone 4C8.1 is a highly specific mouse monoclonal antibody, that targets SV2C & has been tested in western blotting & IHC.
Immunohistochemistry Analysis: A 1:2,000 dilution from a representative lot detected SV2C in human cerebellum and human thalamus tissue.
Research Category
Neuroscience
Research Sub Category
Developmental Signaling

Quality

Evaluated by Western Blotting in mouse brain tissue lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected SV2C in 200 µg of mouse brain tissue lysate.

Target description

~82 kDa observed

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jacquie Maignel et al.
Toxins, 14(2) (2022-02-25)
Management of neurogenic detrusor overactivity (NDO) remains a clinical priority to improve patients' quality of life and prevent dramatic urological complications. Intradetrusor injection of onabotulinumtoxinA (BoNT/A1, botulinum neurotoxin A1) is approved as second therapeutic line in these patients, demonstrating a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service